Published in Iran Biomed J on May 31, 2017
ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol (2002) 7.40
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Subclassification of preeclampsia. Hypertens Pregnancy (2003) 2.25
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
Differential placental gene expression in severe preeclampsia. Placenta (2009) 1.85
A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res (2005) 1.76
Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res (2010) 1.56
Endoglin regulates trophoblast differentiation along the invasive pathway in human placental villous explants. Endocrinology (1997) 1.38
Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab (2004) 1.34
Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol (2008) 1.26
Gene expression in chorionic villous samples at 11 weeks' gestation from women destined to develop preeclampsia. Prenat Diagn (2008) 1.14
First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol (2008) 1.12
Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand (2008) 1.04
Prediction of pre-eclampsia by an analysis of placenta-derived cellular mRNA in the blood of pregnant women at 15-20 weeks of gestation. BJOG (2010) 0.97
Expression of angiogenesis-related genes in the cellular component of the blood of preeclamptic women. Reprod Sci (2009) 0.95
The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Hum Hypertens (2011) 0.90
Soluble endoglin and transforming growth factor-beta1 in women who subsequently developed preeclampsia. Prenat Diagn (2009) 0.90
Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia. PLoS One (2014) 0.88
Role of biomarkers in early detection of preeclampsia. J Clin Diagn Res (2014) 0.88
Variation in endoglin pathway genes is associated with preeclampsia: a case-control candidate gene association study. BMC Pregnancy Childbirth (2013) 0.85
Early Pregnancy Biomarkers in Pre-Eclampsia: A Systematic Review and Meta-Analysis. Int J Mol Sci (2015) 0.81
Association between CRP gene polymorphisms and the risk of preeclampsia in Han Chinese women. Genet Test Mol Biomarkers (2014) 0.80
Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14. Placenta (2015) 0.80
Soluble endoglin production is upregulated by oxysterols but not quenched by pravastatin in primary placental and endothelial cells. Placenta (2014) 0.79
The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia. Iran J Reprod Med (2015) 0.79
Ethical considerations in sex selection. J Educ Health Promot (2015) 0.75
Accuracy of Soluble Endoglin for Diagnosis of Preeclampsia and its Severity Iran Biomed J (2017) 0.75
Expression of placental growth factor mRNA in preeclampsia. Int J Reprod Biomed (Yazd) (2017) 0.75